Phase II, placebo-controlled trial of SAGE-718 on cognitive function in participants with Huntington’s disease
C
Christopher James
Primary Investigator
Recruiting
25-65 years
All
Phase
2
5 participants needed
2 Locations
Overview
Who is Eligible
- Ages 25-65
- Diagnosis of Huntington’s disease
- Able to swallow pills and liquids
- No history of cancer within last 12 months
- No current substance or alcohol abuse (including THC)
- No history of stroke or head injury requiring hospitalization
What is Involved
- In person at IUH Neuroscience Center
Daily oral medication over 12 weeks with participation over a total of 4 months.
Compensation
- Compensation available via payment card for each completed appointment
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Huntingtons disease
-
Age: Between 25 Years - 65 Years
-
Gender: All
Updated on
15 May 2024.
Study ID: 14964
Connect with a study center near you
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
